Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments
Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments PR Newswire Chris Kurtz Appointed Chief Technical Officer Sarah Mathieson Appointed Senior Vice President, Corporate Affairs PALO ALTO, Calif. , April 18, 2022 /PRNewswire/ — Eiger more...
Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET
WARREN, N.J., April 18, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, more...
ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting
YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as more...
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund
CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced more...
Bragar Eagel & Squire, P.C. Is Investigating Corcept, Core Scientific, Anavex, and Roblox and Encourages Investors to Contact the Firm
NEW YORK, April 15, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT), Core Scientific, Inc. (NASDAQ: CORZ), more...
Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) — Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today more...
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
aTyr Pharma, Inc. LIFE announced that the FDA has granted Orphan Drug designation to its lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of systemic sclerosis (SSc, also called scleroderma). The Orphan Drug designation is more...
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022 PR Newswire CRANFORD, N.J. , April 14, 2022 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical more...
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng LAWRENCEVILLE, N.J., April 14, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: more...
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data and analyses of rezafungin, a novel, more...